These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20547641)

  • 1. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use.
    Pilishvili T; Zell ER; Farley MM; Schaffner W; Lynfield R; Nyquist AC; Vazquez M; Bennett NM; Reingold A; Thomas A; Jackson D; Schuchat A; Whitney CG
    Pediatrics; 2010 Jul; 126(1):e9-17. PubMed ID: 20547641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study.
    Barricarte A; Castilla J; Gil-Setas A; Torroba L; Navarro-Alonso JA; Irisarri F; Arriazu M
    Clin Infect Dis; 2007 Jun; 44(11):1436-41. PubMed ID: 17479939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.
    Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP
    Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups.
    Byington CL; Samore MH; Stoddard GJ; Barlow S; Daly J; Korgenski K; Firth S; Glover D; Jensen J; Mason EO; Shutt CK; Pavia AT
    Clin Infect Dis; 2005 Jul; 41(1):21-9. PubMed ID: 15937758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007.
    Hsu KK; Shea KM; Stevenson AE; Pelton SI;
    Pediatr Infect Dis J; 2010 Apr; 29(4):289-93. PubMed ID: 19935447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
    Isaacman DJ; McIntosh ED; Reinert RR
    Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.
    Pilishvili T; Lexau C; Farley MM; Hadler J; Harrison LH; Bennett NM; Reingold A; Thomas A; Schaffner W; Craig AS; Smith PJ; Beall BW; Whitney CG; Moore MR;
    J Infect Dis; 2010 Jan; 201(1):32-41. PubMed ID: 19947881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period.
    De Serres G; Pilishvili T; Link-Gelles R; Reingold A; Gershman K; Petit S; Farley MM; Harrison LH; Lynfield R; Bennett NM; Baumbach J; Thomas A; Schaffner W; Beall B; Whitney C; Moore M
    Vaccine; 2012 Jun; 30(27):4067-72. PubMed ID: 22525797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.
    Albrich WC; Baughman W; Schmotzer B; Farley MM
    Clin Infect Dis; 2007 Jun; 44(12):1569-76. PubMed ID: 17516400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease.
    Weatherholtz R; Millar EV; Moulton LH; Reid R; Rudolph K; Santosham M; O'Brien KL
    Clin Infect Dis; 2010 May; 50(9):1238-46. PubMed ID: 20367225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.
    Millar EV; Watt JP; Bronsdon MA; Dallas J; Reid R; Santosham M; O'Brien KL
    Clin Infect Dis; 2008 Oct; 47(8):989-96. PubMed ID: 18781875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].
    Artiles F; Horcajada I; Cañas AM; Alamo I; Bordes A; González A; Santana M; Lafarga B
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):14-21. PubMed ID: 19217998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive pneumococcal disease in Alaskan children: impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply.
    Wenger JD; Zulz T; Bruden D; Singleton R; Bruce MG; Bulkow L; Parks D; Rudolph K; Hurlburt D; Ritter T; Klejka J; Hennessy T
    Pediatr Infect Dis J; 2010 Mar; 29(3):251-6. PubMed ID: 19952861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.
    Kellner JD; Vanderkooi OG; MacDonald J; Church DL; Tyrrell GJ; Scheifele DW
    Clin Infect Dis; 2009 Jul; 49(2):205-12. PubMed ID: 19508165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.
    Muñoz-Almagro C; Jordan I; Gene A; Latorre C; Garcia-Garcia JJ; Pallares R
    Clin Infect Dis; 2008 Jan; 46(2):174-82. PubMed ID: 18171247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.